Hot Features
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Ms. Eva Anette EngelhardtExec. VP & President of the Clinical Diagnostics Group | -550,00 | 135,60k | Vente | 246,54 | 346,00 | -61,38% |
| 2026-04-24 | Mr. Roop K. LakkarajuExec. VP & CFO | -420,00 | 120,89k | Derivative Exercise and Sale | 287,84 | 2,56k | - |
| 2026-04-24 | Mr. Roop K. LakkarajuExec. VP & CFO | 658,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,56k | 34,52% |
| 2026-04-24 | Ms. Courtney C. EnloeExec. VP, General Counsel & Secretary | -77,00 | 22,16k | Derivative Exercise and Sale | 287,84 | 750,00 | - |
| 2026-04-24 | Ms. Courtney C. EnloeExec. VP, General Counsel & Secretary | 109,00 | 0,00 | Derivative Exercise and Retained Stock | - | 750,00 | 17,00% |
| 2026-04-21 | Mr. Gregory K. HinckleyLead Independent Director | 407,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,22k | 50,37% |
| 2026-04-21 | Ms. Melinda Litherland PeiIndependent Director | 407,00 | 0,00 | Derivative Exercise and Retained Stock | - | 715,00 | 132,14% |
| 2026-04-21 | Mr. Jeffrey L. EdwardsIndependent Director | 407,00 | 0,00 | Derivative Exercise and Retained Stock | - | 715,00 | 132,14% |
| 2026-04-21 | Mr. Arnold A. PinkstonIndependent Director | 407,00 | 0,00 | Derivative Exercise and Retained Stock | - | 715,00 | 132,14% |
| 2025-11-06 | Mr. James J. BarryExec. VP & President of Life Science Group | -699,87 | 214,29k | Vente | 306,18 | 510,00 | -57,85% |
| 2025-10-24 | Mr. Jonathan P. DiVincenzoPresident & COO | 919,00 | 0,00 | Derivative Exercise and Retained Stock | - | 919,00 | - |
| 2025-10-24 | Mr. Jonathan P. DiVincenzoPresident & COO | -950,00 | 322,76k | Derivative Exercise and Sale | 339,75 | 919,00 | - |
| 2025-10-20 | Mr. Sedat EvranExec. VP of Global Supply Chain | 709,00 | 0,00 | Derivative Exercise and Retained Stock | - | 2,23k | 46,52% |
| 2025-10-20 | Mr. Sedat EvranExec. VP of Global Supply Chain | -335,00 | 107,84k | Derivative Exercise and Sale | 321,90 | 2,23k | - |
| 2025-09-06 | Mr. Sedat EvranExec. VP of Global Supply Chain | 587,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,52k | 62,65% |
| 2025-09-06 | Mr. Sedat EvranExec. VP of Global Supply Chain | -277,00 | 81,83k | Derivative Exercise and Sale | 295,43 | 1,52k | - |
| 2025-09-06 | Mr. Roop K. LakkarajuExec. VP & CFO | 985,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,84k | 114,67% |
| 2025-09-06 | Mr. Roop K. LakkarajuExec. VP & CFO | -550,00 | 162,49k | Derivative Exercise and Sale | 295,43 | 1,84k | - |
| 2025-09-06 | Ms. Colleen CoreyInitié | 367,00 | 0,00 | Derivative Exercise and Retained Stock | - | 19,55k | 1,91% |
| 2025-09-06 | Ms. Colleen CoreyInitié | -209,00 | 61,74k | Derivative Exercise and Sale | 295,43 | 19,55k | - |
| 2025-09-06 | Mr. James J. BarryExec. VP & President of Life Science Group | 678,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,21k | 127,44% |
| 2025-09-06 | Mr. James J. BarryExec. VP & President of Life Science Group | -378,00 | 111,67k | Derivative Exercise and Sale | 295,43 | 1,21k | - |
| 2025-09-06 | Ms. Allison SchwartzDirector | 59,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,46k | 4,22% |
| 2025-09-06 | Ms. Allison SchwartzDirector | -33,00 | 9,75k | Derivative Exercise and Sale | 295,43 | 1,46k | - |
| 2025-09-06 | Ms. Eva Anette EngelhardtExec. VP & President of the Clinical Diagnostics Group | 739,00 | 0,00 | Derivative Exercise and Retained Stock | - | 896,00 | 470,70% |
| 2025-09-06 | Ms. Eva Anette EngelhardtExec. VP & President of the Clinical Diagnostics Group | -413,00 | 122,01k | Derivative Exercise and Sale | 295,43 | 896,00 | - |
| 2025-09-06 | Mr. Norman D. SchwartzChairman & CEO | 1,93k | 0,00 | Derivative Exercise and Retained Stock | - | 807,08k | 0,24% |
| 2025-09-06 | Mr. Norman D. SchwartzChairman & CEO | -1,53k | 451,42k | Derivative Exercise and Sale | 295,43 | 807,08k | - |
| 2025-09-06 | Ms. Courtney C. EnloeExec. VP, General Counsel & Secretary | 493,00 | 0,00 | Derivative Exercise and Retained Stock | - | - | - |
| 2025-09-06 | Ms. Courtney C. EnloeExec. VP, General Counsel & Secretary | -275,00 | 81,24k | Derivative Exercise and Sale | 295,43 | - | - |
| 2025-09-01 | Ms. Allison SchwartzDirector | 92,00 | 0,00 | Derivative Exercise and Retained Stock | - | 1,40k | 7,05% |
| 2025-09-01 | Ms. Allison SchwartzDirector | -55,00 | 16,38k | Derivative Exercise and Sale | 297,88 | 1,40k | - |
| 2025-09-01 | Mr. James J. BarryExec. VP & President of Life Science Group | 385,00 | 0,00 | Derivative Exercise and Retained Stock | - | 532,00 | 261,90% |
| 2025-09-01 | Mr. James J. BarryExec. VP & President of Life Science Group | -217,00 | 64,64k | Derivative Exercise and Sale | 297,88 | 532,00 | - |
| 2025-09-01 | Ms. Colleen CoreyInitié | 704,00 | 0,00 | Derivative Exercise and Retained Stock | - | 19,18k | 3,81% |
| 2025-09-01 | Ms. Colleen CoreyInitié | -398,00 | 118,56k | Derivative Exercise and Sale | 297,88 | 19,18k | - |
| 2025-09-01 | Mr. Norman D. SchwartzChairman & CEO | 3,27k | 0,00 | Derivative Exercise and Retained Stock | - | 805,15k | 0,41% |
| 2025-09-01 | Mr. Norman D. SchwartzChairman & CEO | -3,08k | 918,66k | Derivative Exercise and Sale | 297,88 | 805,15k | - |
| 2025-07-25 | Ms. Eva Anette EngelhardtExec. VP & President of the Clinical Diagnostics Group | 157,00 | 0,00 | Derivative Exercise and Retained Stock | - | 157,00 | - |
| 2025-07-25 | Ms. Eva Anette EngelhardtExec. VP & President of the Clinical Diagnostics Group | -88,00 | 23,25k | Derivative Exercise and Sale | 264,19 | 157,00 | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.